Principal Financial Group Inc. Raises Holdings in Catalent, Inc. (NYSE:CTLT)

Principal Financial Group Inc. boosted its position in Catalent, Inc. (NYSE:CTLT) by 1.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 214,545 shares of the company’s stock after buying an additional 2,677 shares during the period. Principal Financial Group Inc. owned approximately 0.13% of Catalent worth $28,550,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Catalent by 0.3% in the second quarter. Vanguard Group Inc. now owns 18,331,319 shares of the company’s stock valued at $1,981,982,000 after buying an additional 47,141 shares during the last quarter. BlackRock Inc. boosted its position in Catalent by 2.4% in the second quarter. BlackRock Inc. now owns 14,324,097 shares of the company’s stock valued at $1,548,720,000 after buying an additional 335,336 shares during the last quarter. State Street Corp boosted its position in Catalent by 3.8% in the second quarter. State Street Corp now owns 6,613,376 shares of the company’s stock valued at $715,038,000 after buying an additional 240,541 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Catalent by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 4,748,293 shares of the company’s stock valued at $513,386,000 after buying an additional 232,981 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Catalent by 0.7% in the second quarter. Northern Trust Corp now owns 1,676,029 shares of the company’s stock valued at $181,212,000 after buying an additional 11,115 shares during the last quarter. Hedge funds and other institutional investors own 97.12% of the company’s stock.

Shares of CTLT stock opened at $108.24 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.59 and a quick ratio of 3.02. The company has a market cap of $18.53 billion, a price-to-earnings ratio of 34.15, a PEG ratio of 1.86 and a beta of 1.32. The stock has a 50 day simple moving average of $124.44 and a 200-day simple moving average of $125.70. Catalent, Inc. has a 1-year low of $97.86 and a 1-year high of $142.64.

Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 1st. The company reported $0.71 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.06. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a return on equity of 14.64% and a net margin of 13.68%. During the same period in the prior year, the company posted $0.33 EPS. Analysts anticipate that Catalent, Inc. will post 3.51 earnings per share for the current fiscal year.

In related news, CFO Thomas P. Castellano sold 2,307 shares of the business’s stock in a transaction that occurred on Wednesday, October 20th. The stock was sold at an average price of $134.00, for a total transaction of $309,138.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karen Flynn sold 2,472 shares of the business’s stock in a transaction that occurred on Monday, January 10th. The stock was sold at an average price of $116.64, for a total value of $288,334.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,009,847 shares of company stock valued at $389,142,882. Corporate insiders own 0.53% of the company’s stock.

CTLT has been the topic of a number of recent research reports. Zacks Investment Research upgraded Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 target price on the stock in a research report on Tuesday, January 4th. Barclays assumed coverage on Catalent in a report on Thursday, December 16th. They issued an “overweight” rating and a $160.00 price target for the company. Royal Bank of Canada boosted their price target on Catalent from $145.00 to $155.00 and gave the company an “outperform” rating in a report on Wednesday, November 3rd. Finally, Morgan Stanley boosted their price target on Catalent from $147.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, November 3rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $153.33.

About Catalent

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Article: Gross Domestic Product (GDP)

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.